➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Baxter
McKinsey
Harvard Business School
McKesson
Express Scripts

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

TENORMIN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Tenormin patents expire, and what generic alternatives are available?

Tenormin is a drug marketed by Astrazeneca and Alvogen and is included in two NDAs.

The generic ingredient in TENORMIN is atenolol. There are thirty-four drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the atenolol profile page.

US ANDA Litigation and Generic Entry Outlook for Tenormin

A generic version of TENORMIN was approved as atenolol by ALVOGEN on July 15th, 1988.

  Start Trial

Drug patent expirations by year for TENORMIN
Drug Prices for TENORMIN

See drug prices for TENORMIN

Recent Clinical Trials for TENORMIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
High Risk Obstetrical ConsultantsEarly Phase 1
University of Tennessee Graduate School of MedicineEarly Phase 1
BioHealthonomics Inc.Phase 2

See all TENORMIN clinical trials

Pharmacology for TENORMIN
Paragraph IV (Patent) Challenges for TENORMIN
Tradename Dosage Ingredient NDA Submissiondate
TENORMIN TABLET;ORAL atenolol 018240

US Patents and Regulatory Information for TENORMIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca TENORMIN atenolol INJECTABLE;INJECTION 019058-001 Sep 13, 1989 DISCN Yes No   Start Trial   Start Trial   Start Trial
Alvogen TENORMIN atenolol TABLET;ORAL 018240-002 Approved Prior to Jan 1, 1982 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Alvogen TENORMIN atenolol TABLET;ORAL 018240-004 Apr 9, 1990 AB RX Yes No   Start Trial   Start Trial   Start Trial
Alvogen TENORMIN atenolol TABLET;ORAL 018240-001 Approved Prior to Jan 1, 1982 AB RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TENORMIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alvogen TENORMIN atenolol TABLET;ORAL 018240-002 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Alvogen TENORMIN atenolol TABLET;ORAL 018240-004 Apr 9, 1990   Start Trial   Start Trial
Alvogen TENORMIN atenolol TABLET;ORAL 018240-001 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Alvogen TENORMIN atenolol TABLET;ORAL 018240-001 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Mallinckrodt
Dow
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.